A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056)

NCT01431534 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: Ridaforolimus

Sponsor

Merck Sharp & Dohme LLC